Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16729648 | 0.88 | — | — | |
| Bromide SCHEMBL16717265 | 0.86 | — | — | |
| SCHEMBL1800727 | 0.77 | CCNT1 (0.30) | CCNT1CDK9 | |
| SCHEMBL7925552 | 0.77 | MAPT (0.35) | CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL8156603 | 0.76 | — | — | |
| SCHEMBL12265082 | 0.73 | SSTR4 (0.32) | CCNT1CDK9 | |
| SCHEMBL5151795 | 0.73 | CYP11B1 (0.38) | — | |
| SCHEMBL4206342 | 0.73 | DRD2 (0.33) | CCNT1CDK9 | |
| SCHEMBL18013173 | 0.73 | MAPT (0.36) | CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL4194850 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12234245-B2 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3823974-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-112513048-A | Sulfonylimide compounds as inhibitors of interleukin-1 activity | 豪夫迈·罗氏有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3240791-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2017170765-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 | 2017-10-05 | — | — | WO | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | CHRNB2 4342/4885CHRNA4 4308/4885CCNT1 358/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | CHRNB2 4342/4885CHRNA4 4308/4885CCNT1 358/4885 |
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | CHRNB2 4788/4885CHRNA4 4807/4885CCNT1 4454/4885 |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | CHRNB2 4342/4885CHRNA4 4308/4885CCNT1 358/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | CHRNB2 851/4885CHRNA4 1377/4885CCNT1 4564/4885 |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | CHRNB2 4788/4885CHRNA4 4807/4885CCNT1 4454/4885 |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | CHRNB2 4390/4885CHRNA4 4350/4885CCNT1 363/4885 |
| US-12234245-B2 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | IL1A, IL18, IL1B | CHRNB2 4788/4885CHRNA4 4807/4885CCNT1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.